1.png){kind=logo}
Transforming the future of precision medicine.
#KeepYourThyroid
#SaveThyroids
#DesignToPredictBenign
GeneproDX offers an exciting investment opportunity through ThyroidPrint®, an innovative cancer diagnostic product developed in partnership with Biocartis®. ThyroidPrint® unique decentralized model enables global accessibility, addressing the critical need for rapid and accurate thyroid nodule diagnosis. This positions GeneproDX as a promising player in the future of healthcare investment.
Our decentralized model, enabled by the Idylla™ Platform, allows tests to be performed in just 3 hours in more than countries.
Market Access across five continents, including USA
ThyroidPrint®, as the first and currently the only test for Indeterminate Thyroid Nodules (ITN) available in EU and LATAM, is paving the way in a market worth $1.8 billion annually. With an active customer service for patients and physicians, our strategic plan is to solidify our leadership in the EU and LATAM before expanding into the U.S. market by 2025 and Canada, Middle East, Asia & Oceania by 2026.
Annually 1.25 M thyroid FNA biopsies are reported as indeterminate. In ITN, the risk of cancer is 25%, therefore surgery is recommended in most cases.
Approximately, 3 out of 4 surgeries for ITN are benign, resulting in an unacceptably high rate of unnecessary surgeries (900k/year globally)
In the US, unnecessary ITN surgeries cost the health system approximately US $1.26 B/year*
The experienced leadership team, advisors and board members who are guiding GeneproDX vision and ensuring our innovative approach to precision medicine reaches every corner of the globe.
Executive Team
Professor of Surgery P. Universidad Católica de Chile
Santiago, Chile
Global Strategy & Operations
Barcelona, Spain
LATAM Business Development an Sales
Santiago, Chile
Board
Business Strategy Advisor
San Francisco, CA
.png)
EVP, Strategy & Corporate Development at Berkeley Lights
San Diego, CA
CEO at Family Office Girona Investment Miami, Florida
General Partner at Fondo Alerce Venture Capital
Santiago, Chile
Professor of Surgery P. Universidad Católica de Chile
Santiago, Chile
Transforming the future of precision medicine.
#KeepYourThyroid
#SaveThyroids
#DesignToPredictBenign
